Please ensure Javascript is enabled for purposes of website accessibility
Todd Campbell

Todd Campbell


Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent articles


Independent Monitors Suggest Shorter Timeline for Novocure's Lung Cancer Treatment

A trial examining the use of Novocure's tumor-treating field technology in non-small cell lung cancer patients could enroll fewer patients over a shorter period, based on recommendations by an independent committee.


bluebird bio Says Its Drug "Unlikely" to Have Caused Blood Cancer

A clinical hold on the biotech company could be lifted following Bluebird's results.


Warren Buffett Just Bought These Stocks

Berkshire Hathaway's 13-F filing shows the Oracle of Omaha's bullish on healthcare.


Amazon Opens an Online Pharmacy

The e-commerce giant's new pharmacy will deliver prescription drugs throughout most of the U.S.


Supreme Court May Side With Obamacare Again

Comments by conservative justices suggest the Affordable Care Act can continue without an individual mandate.


Why Fulgent Genetics Stock Is Soaring 11.2% Today

Coronavirus testing demand caused revenue and profit to surge last quarter.


Why Seagen Shares Are Tumbling 12.5% Today

A broad market sell-off is trumping third-quarter results that outpaced analyst expectations.


Abiomed's Heart Pump Can Improve Outcomes in Some Patients

New trial data supports the use of the company's Impella heart pumps in high-risk patients undergoing surgery to treat their coronary heart disease.


Why Selecta Biosciences Tumbled 34% Today

Disappointing phase 2 data casts doubt on SEL-212's future.


Here's Why Healthcare Stocks Are Falling This Week

Justice Ruth Bader Ginsburg's death jeopardizes Obamacare's future, and that puts healthcare companies' revenue at risk.


FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy

The Food and Drug Administration's acceptance means it will issue a go/no-go decision on ide-cel in March 2021.


Roche Spends $451 Million to Acquire Inflazome's NLRP3 Program

The deal will provide the pharma giant with a unique new platform for tackling autoimmune diseases.


AstraZeneca's Lynparza Delivers Progression-Free Survival of Over 4 Years in Advanced Ovarian Cancer

The latest results from a long-term study of the drug enhance the case for its use.


Moderna Plans to Produce 20 Million Doses of Its COVID-19 Vaccine Candidate in 2020

The biotech is ramping up production ahead of the results from its late-stage clinical study of mRNA-1273.


New York Files Charges Against Johnson & Johnson Over Opioid Marketing

The healthcare giant is being charged with insurance fraud.


Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

Bristol-Myers Squibb has come to terms on an agreement to delay entry of a generic version of its multiple myeloma drug, Revlimid.


Moderna Opens Its First Commercial Office in Europe

Its new operations in Switzerland will boost its EU presence as it aims to bring a COVID-19 vaccine to market worldwide.


Germany Awards $743 Million to BioNTech and CureVac for Coronavirus Vaccine Development

BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.


Merck Inks Multibillion-Dollar Deal With Seattle Genetics, Including Equity

Merck is acquiring $1 billion in Seattle Genetics shares as part of a wide-ranging collaboration agreement.


Pfizer Says It Could Know If Its COVID-19 Vaccine Candidate Works in October

The drugmaker's CEO said there was a more than 60% chance that they would know by the end of next month if BNT162b2 is effective.